Clinical Trials Sponsored by BioCis Pharma Ltd

Total 1252 results

BioCis Pharma Ltd

Completed

Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

Finland
BioCis Pharma Ltd
Turku University Hospital; FinnMedi Oy; Tampere University Hospital

Completed

Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

Finland
BioMAS Ltd

Unknown

Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts

External Genital Warts

Israel
BioMAS Ltd

Terminated

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Chemotherapy Induced Thrombocytopenia

Israel
BioMAS Ltd

Withdrawn

Topical Application of AS101 for the Treatment of Psoriasis

Mild to Moderate Psoriasis

Israel
BioMAS Ltd

Suspended

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
BioMAS Ltd

Terminated

Topical Application of AS101 for the Treatment of Atopic Dermatitis

Atopic Dermatitis

Israel
BioMAS Ltd

Completed

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Condyloma Acuminata | Wart; External Genital Organs

Israel
Biohit Healthcare Ltd

Unknown

Gastropanel for Gastric Atrophy and Cancer Risk Assessment

Stomach Neoplasms | Gastritis, Atrophic

United Kingdom
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd

Active, not recruiting

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis (STELLAR-2)

Moderate to Severe Chronic Plaque Psoriasis

United States
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
Biocon Biologics UK Ltd

Active, not recruiting

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis (DEVOTE)

Postmenopausal Women With Osteoporosis

United Kingdom
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors (BC3195)

Locally Advanced or Metastatic Solid Tumors

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Small Cell Lung Cancer

China
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

Healthy

France, United States
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects

Healthy

Germany
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

Healthy

Belgium
Samsung Bioepis Co., Ltd.

Completed

A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer

Korea, Republic of, Germany, Hungary, Taiwan, Thailand, Georgia, Serbia, Poland, Romania, Ukraine, Spain, Belarus, Russian Federation
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects

Healthy

Germany
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

HER2 Positive Early or Locally Advanced Breast Cancer

Czechia
Samsung Bioepis Co., Ltd.

Completed

A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Rheumatoid Arthritis

Poland, United Kingdom
Samsung Bioepis Co., Ltd.

Completed

A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Rheumatoid Arthritis

Lithuania, Poland
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Georgia, India, Romania, Spain
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Diabetic Kidney Disease | IgA Nephropathy

China
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Thailand, Romania, India, Mexico, Ukraine
Samsung Bioepis Co., Ltd.

Terminated

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Breast Neoplasms

Ukraine, Romania, Russian Federation, France, Bulgaria, Czechia, Poland
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

Healthy

France
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Samsung Bioepis Co., Ltd.

Completed

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Poland
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects

Healthy

Belgium, New Zealand
Samsung Bioepis Co., Ltd.

Completed

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Poland
Samsung Bioepis Co., Ltd.

Completed

A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Rheumatoid Arthritis

Bulgaria, Lithuania
N4 Pharma UK Ltd.
BDD Pharma Ltd

Completed

Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

Erectile Dysfunction

United Kingdom
Biocon Biologics Inc.
MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. Ltd

Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis

Bulgaria, Czechia, Estonia, Poland
Biocon Biologics UK Ltd
Biotrial

Completed

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS (DENARIUS)

Healthy Volunteers

United States
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Advanced Ovarian Cancer | Serous Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML

Hematologic Malignancy

China
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
Samsung Bioepis Co., Ltd.

Completed

A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

Macular Edema | Retinal Vein Occlusion | Neovascular Age-related Macular Degeneration

Poland
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

Poland
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects

Healthy

Germany
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects

Healthy

Germany
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects

Healthy

Germany
Samsung Bioepis Co., Ltd.

Completed

Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects

Healthy

Netherlands

3

Subscribe